Dataset Categories Navigation - Datasets - Datasets

Datasets

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

This is an open-label extension to study 49653/461, to assess the long-term safety of rosiglitazone (extended-release tablets) in subjects with mild to moderate Alzheimer's Disease. For more information…

DPUK Synthetic Dataset

Data from three population cohorts were used to create a synthetic dataset (synth1.0) for system development, methods development and training purposes. The synthetic dataset does not contain any personally…

Critical Path for Alzheimer's Disease (CPAD) Database

Patient-level, control-arm data from multiple aggregated studies of AD and MCI. The database contains, but is not limited to, demographic information, APOE4 genotype, concomitant medications, and cognitive…

Effects of LY450139, on the Progression of Alzheimer's Disease as Compared with Placebo

Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta amyloid (β-amyloid), a sticky…

Plasma microRNA biomarker detection for mild cognitive impairment using differential correlation analysis - GSE90828

Mild cognitive impairment (MCI) is an intermediate state between normal aging, and Alzheimer’s disease, and other dementias. Early detection of dementia, and MCI, is a crucial issue in terms of secondary…

Synthetic EPAD Dataset

This synthetic dataset has been modeled after data from the European Prevention of Alzheimer's Dementia (EPAD) project (http://ep-ad.org/). The dataset consists of 10 tables and contains data for 200 subjects…

The GERAS Study - Japan

GERAS Japan was an 18-month, prospective, multicenter, longitudinal, observational study conducted in 30 sites in different regions in Japan, designed to evaluate the costs and resource use associated…

EPAD LCS v500.0

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset . European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V500.0 data release…

A Single Blind, Placebo-controlled, Randomised Study in Mild to Moderate Alzheimer's Disease Patients to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK239512, a Selective...

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimer's disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated…

An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population

The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current…

Brain long read sequencing

What is it and what does it include? Long read brain DNA and RNA from brains processed at NIH’s Center for Alzheimer’s Disease and Related Dementias (CARD). Please see the publication for additional…

MindADmini

MIND-ADmini is a multinational proof-of-concept 6-month randomized controlled trial (RCT), with four trial sites (Sweden, Finland, Germany, France). The trial targeted individuals with prodromal Alzheimer…

Honolulu-Asia Aging Study

The Honolulu-Asia Aging Study (HAAS) was a longitudinal aging study examining the prevalence and risk factors for dementia in over 3,000 male participants. HAAS was established in 1991 as an extension…

Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease

The DAC Early Detection Program - Indiana University

The DAC Early Detection Program - Indiana University Forum Page: (1) Criteria for Access to Indiana University’s DAC Project Data - The DAC Early Detection Program - Indiana University - Datasets - AD…

The GERAS II Study

The GERAS II study was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers in Italy and Spain…

RNAseq in Alzheimer's Disease patients - GSE53697

Human brain samples were obtained from the Mount Sinai Brain Bank; RNA was Trizol extracted, Ribominus selected and submitted for high-throughput sequencing. Human brain samples from control and advanced…

Effect of LY450139 on the Long-Term Progression of Alzheimer's Disease

Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (β-amyloid), a sticky…

Detection of Alzheimer’s Disease at Mild Cognitive Impairment and Disease Progression Using Autoantibodies as Blood-based Biomarkers - GSE74763

Human serum samples from Alzheimer's disease driven mild cognitive impairment and non-diseased controls were probed onto human protein microarrays in order to identify differentially expressed autoantibody…

The English Longitudinal Study of Ageing

The primary objective of the English Longitudinal Study of Ageing (ELSA) is to collect longitudinal multidisciplinary data from a representative sample of the English population aged 50 to 100 at recruitment…

Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease

This is a placebo-controlled study evaluating the effects of rosiglitazone on functional brain activity and cognition in patients with mild to moderate Alzheimer's Disease (AD). For more information…

A double-blind, randomised, placebo-controlled, parallel-group dose-ranging study to investigate the effects of rosiglitazone on cognition in subjects with mild to moderate Alzheimer's disease

What is it and what does it include? This phase II study was designed to determine the safety profile and treatment effects of rosiglitazone (RSG) in subjects with mild to moderate Alzheimer’s disease…

Banner Alzheimer's Prevention Initiative - Gen1 Gen2

The Alzheimer’s Prevention Initiative Generation Study, a Generation Program (API Generation) that comprises two separate clinical trials, Generation Study 1 (Gen1) and Generation Study 2 (Gen2). These…

ADDIA Alzheimer's Disease Diagnostics Clinical Study

ADDIA is a multicenter prospective clinical cohort comprised of Alzheimer’s disease (AD), non-Alzheimer’s neurodegenerative diseases (NAD), and control healthy subjects aged 40 to 85 years recruited from…

A reference induced pluripotent stem cell line for large-scale collaborative studies

What is it and what does it include? Human induced pluripotent stem cell (iPSC) lines are a powerful tool for studying development and disease, but the considerable phenotypic variation between lines…

An Open-label Extension to Study AVA102670 and AVA102672, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended-Release Tablets) as Adjunctive Therapy on Cognition in Subjects With Mild...

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed either AVA102670 or AVA102672…

An Open-label Extension to Study AVA105640, to Assess the Long-term Safety and Efficacy of Rosiglitazone (Extended-Release Tablets) on Cognition in Subjects With Mild to Moderate Alzheimer's Disease

This is a Phase III, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate Alzheimer's disease (AD) who have completed AVA105640. All subjects will…

The Airwave Health Monitoring study

What is it and what does it include? The Airwave Health Monitoring Study was established in 2004 to investigate possible long-term health effects associated with use of TETRA, the radio system used by…

EPAD LCS v1500.0

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset. European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V1500.0 data release…

AD Synthetic Patient Data

A synthetic dataset based on the Critical Path for Alzheimer's Disease (CPAD) collection of patient data from control arms of clinical trials for Alzheimer's Disease (AD) and Mild Cognitive Impairment…

Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's Disease

The purposes of this study are to determine: The safety of LY450139 dihydrate and any side effects that might be associated with it. How much LY450139 dihydrate should be given and how long it may…

Alzheimer's Prevention Virtual Cohort

A synthetic dataset of pre-clinical dementia patients, generated using privacy-preserving generative deep learning techniques, based on the EPAD LCS V1500.0 dataset. As well as benchmarking against a series…

A blood based 12-miRNA signature of Alzheimer patients - GSE46579

What is it and what does it include? Investigators in this study applied Next-Generation Sequencing (NGS) to miRNAs from blood samples of 48 AD patients and 22 unaffected controls, yielding a total of…

A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of the H3 Receptor Antagonist, GSK239512 in Subjects With Mild to Moderate Alzheimer's Disease

What is it and what does it include? This study aims to evaluate the cognitive enhancing effects and tolerability of GSK239512 compared to placebo in patients with mild to moderate Alzheimer's. This…

Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients with Mild Alzheimer's Disease or Mild Cognitive Impairment

This is a phase I, an open label, single dose, and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI…

Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease

Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose…

EPAD LCS v.IMI

A key achievement of the European Prevention of Alzheimer's Dementia (EPAD) project ( http://ep-ad.org/ ) was the establishment of a Longitudinal Cohort Study (LCS) that has screened a total of 2,096 participants…

Rosiglitazone (Extended-Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended-release tablets), donepezil, and placebo as monotherapy on cognition and overall…

BLSA Open Data

What is it and what does it include? The National Institute on Aging’s Baltimore Longitudinal Study of Aging (BLSA) is America's longest-running scientific study of human aging. It began in 1958; today…

Mis-spliced transcripts generate de novo proteins in TDP-43-related ALS/FTD

Coordinated transcriptomic and proteomic studies of TDP-43 depleted iPSC-derived neurons to identify numerous peptides that mapped to cryptic exons. Mis-spliced proteins identified in iPSC neurons were…

EPAD LCS v500.1

Please note that a more recent version of these data can be found in the EPAD LCS v.IMI dataset. European Prevention of Alzheimer's Disease (EPAD) Longitudinal Cohort Study (LCS) V500.1 data release…

10/66

The 10/66 dementia research program is a population-based study comprising in principle all older residents aged 65 years and over, living in 11 geographically defined urban and rural catchment area sites…

Whole-blood RNA seq data derived from C9orf72+FTD spectrum cases and controls

Manuscript available: Radiogenomics of C9orf72 expansion carriers reveals global transposable element de-repression and enables prediction of thalamic atrophy and clinical impairment To learn more, visit…

The GERAS Study - US

The GERAS Study - US was a prospective, multicenter, observational study that aimed to assess societal costs and resource use associated with AD among patients and their primary caregivers across 76 sites…

BLSA Synthetic Data

What is it and what does it include? This dataset represents SYNTHETIC data generated off of the real data collected by The National Institute on Aging’s Baltimore Longitudinal Study of Aging (BLSA)…

PREVENT Dementia Research Programme

The PREVENT Dementia programme aims to identify the earliest signs of dementia, which may occur in the brain decades before symptoms appear. Participants were recruited in midlife (aged 40 – 59) to identify…

A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients with...

What is it and what does it include? This phase I interventional study assesses single and repeat doses of GSK933776 (a Beta-amyloid (Aβ) antibody) in patients with Alzheimer's disease. A total of 50…

Alzheimer's Disease and Healthy Aging Data

The Alzheimer’s Disease and Healthy Aging Data provides access to national and state level CDC data on a range of key indicators of health and well-being for older adults, including: Caregiving, Subjective…

Rosiglitazone (Extended-Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

AMYPAD PNHS (Harmonised and Derived) V202306

The Amyloid Imaging to Prevent Alzheimer’s Disease (AMYPAD) Prognostic and Natural History Study (PNHS) is an open-label, prospective, multicentre, cohort study linked to a variety of European Parent Cohorts…

A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease

What is it and what does it include? The study included 124 people between the ages of 50 and 80 with mild to moderate Alzheimer's disease and compared 250 mg of Rilapladib taken once daily to placebo…

A Study of Semagacestat for Alzheimer's Patients

The primary objective of the original study was to assess the safety of semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is…

The GERAS Study - EU

GERAS is an 18-month, multicentre, prospective, non-interventional cohort study conducted in France, Germany, and the UK, designed to evaluate the costs and resource use associated with AD dementia for…

An open-label extension to study AVA100193, to assess the long-term safety and efficacy of rosiglitazone (extended release tablets) in subjects with mild to moderate Alzheimer's disease

For more information on this study, visit the Study Record Detail of the respective clinical trial here . Manuscripts citing this dataset Clinical Study Report here . Scientific Results Summary…